Tufts teams combine stenting and SBRT for Boston Terrier

A new Tufts case spotlight is putting a clinical spotlight on multidisciplinary care for canine heart base tumors. At the Henry and Lois Foster Hospital for Small Animals, cardiology and oncology specialists treated a Boston Terrier named Arnie for a chemodectoma using vascular stenting followed by stereotactic body radiation therapy, with Tufts reporting a 70% reduction in tumor size and better quality of life. The case centers on a problem many general practitioners and emergency teams recognize: these tumors may be slow-growing, but once they compress nearby vessels or cardiac structures, the clinical picture can change quickly. (vet.tufts.edu)

That backdrop matters because chemodectomas occupy an awkward space in small-animal oncology and cardiology. Specialty guidance from NC State notes that chemodectomas, also called aortic body tumors or paragangliomas, are more common in short-nosed breeds such as Boston Terriers and Boxers. They’re often found incidentally, but when they become symptomatic, it’s usually because they’ve enlarged enough to press on the heart or great vessels, leading to signs such as weakness, cough, respiratory difficulty, ascites, or other evidence of cardiovascular compromise. Surgery is often not feasible because of tumor location, which pushes clinicians toward multimodal management. (hospital.cvm.ncsu.edu)

That’s where Arnie’s reported treatment sequence stands out. Tufts said the case required both specialized expertise and close coordination between Cardiology and the Harrington Oncology service. The use of vascular stenting first suggests the immediate priority was relieving hemodynamic obstruction or compression before moving to local tumor control with SBRT. That approach is consistent with published veterinary experience: a 2024 Frontiers in Veterinary Science case report described immediate symptomatic relief after endovascular stenting for right pulmonary artery compression caused by a chemodectoma, while also noting that radiation therapy, chemotherapy, and selected surgical approaches remain part of the treatment toolbox. (frontiersin.org)

The radiation component also fits with the small but growing evidence base for heart base tumors in dogs. A six-dog case series on stereotactic body radiation therapy reported effective tumor-volume reduction in presumed chemodectomas, with the authors concluding that the protocol may improve quality of life for symptomatic dogs even though long-term survival impact remains less clear. NC State’s clinical guidance similarly says these tumors often shrink after radiation and may decrease by 50% or more within the first three to four months after SRT, while stressing that case selection is critical. (sciencedirect.com)

Tufts is also structurally set up for this kind of case. The Harrington Oncology Service lists medical oncology, radiation oncology, and clinical trials under one collaborative umbrella, and its residency and internship materials emphasize routine coordination with cardiology, anesthesia, imaging, and other specialties. Foster Hospital’s cardiology service has separately highlighted its collaboration with oncology on advanced cardiac patients and noted faculty interests in cardio-oncology and catheter-based procedures. In other words, Arnie’s case is notable, but it isn’t a one-off workflow invented for a press release; it reflects an institutional model built around multidisciplinary referral care. (vet.tufts.edu)

Why it matters: For practicing veterinarians, the bigger takeaway is less about one Boston Terrier and more about referral timing and case framing. Dogs with suspected chemodectoma may need more than symptom management if imaging suggests vascular compression, pulmonary outflow compromise, or progressive clinical signs. Published reports indicate stenting can provide fast palliation of obstruction, while SBRT can reduce tumor burden with relatively few treatments compared with conventional fractionation. That creates a meaningful option set for pet parents who may not have considered advanced intervention for a tumor long viewed as slow-moving or largely untreatable because of location. (frontiersin.org)

There’s also a communication point here for primary care teams. Because chemodectomas can be presumptively diagnosed by imaging and may remain indolent for some time, it can be easy to default to monitoring until signs escalate. But specialty guidance recommends staging for metastasis and reassessment when tumors begin affecting heart or vessel function, and the emerging literature suggests outcomes may improve when clinicians match the intervention to the dominant problem, whether that’s obstruction, effusion risk, or local tumor progression. (hospital.cvm.ncsu.edu)

What to watch: Expect more attention on combined interventional cardiology and radiation protocols for heart base tumors, along with continued reporting on which dogs benefit most, how durable stent relief is, and whether multimodal treatment can extend survival as well as comfort. (frontiersin.org)